🇺🇸 FDA
Patent

US 12268660

Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

granted A61KA61K31/167A61K31/216

Quick answer

US patent 12268660 (Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension) held by Aardvark Therapeutics, Inc. expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aardvark Therapeutics, Inc.
Grant date
Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/167, A61K31/216, A61K45/06, A61P